Skip to main content
SpringerLink
Log in

Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study—Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Grönberg H, Adolfsson J, Aly M et al (2015) Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. doi:10.1016/S1470-2045(15)00361-7

    PubMed  Google Scholar 

  2. Welch HG, Gorski DH, Albertsen PC (2015) Trends in metastatic breast and prostate cancer-lessons in cancer dynamics. N Engl J Med 373:1685–1687. doi:10.1056/NEJMp1510443

    Article  PubMed  Google Scholar 

  3. Arnsrud Godtman R, Holmberg E, Lilja H et al (2014) Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol 68:354–360. doi:10.1016/j.eururo.2014.12.006

    Article  PubMed  Google Scholar 

  4. Nordström T, Aly M, Clements MS et al (2013) Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003–2011. Eur Urol 63:419–425. doi:10.1016/j.eururo.2012.10.001

    Article  PubMed  Google Scholar 

  5. Drazer MW, Huo D, Eggener SE (2015) National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 33:2416–2423. doi:10.1200/JCO.2015.61.6532

    Article  PubMed  Google Scholar 

  6. Rider JR, Sandin F, Andrén O et al (2013) Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 63:88–96. doi:10.1016/j.eururo.2012.08.001

    Article  PubMed  Google Scholar 

  7. Grönberg H, Adolfsson J, Aly M et al (2016) Abstract 86: the STHLM3 model improves prostate cancer testing in men 50–69 years—further health economic and clinic evaluation. Eur Urol Suppl 15:1–1167. doi:10.1016/S1569-9056(16)60088-X

    Article  Google Scholar 

Download references

Authors’ contributions

ME was involved in project development, data analysis, and manuscript writing. HG developed the project, collected data, and wrote the manuscript. TN collected data and wrote the manuscript.

Author information

Authors and Affiliations

  1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77, Stockholm, Sweden

    Tobias Nordström, Martin Eklund & Henrik Grönberg

  2. Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, 182 88, Stockholm, Sweden

    Tobias Nordström

Authors
  1. Tobias Nordström
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Eklund
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henrik Grönberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tobias Nordström.

Ethics declarations

Conflict of interest

HG has five prostate cancer diagnostic-related patents pending, has patent applications licensed to Thermo Fisher Scientific, and might receive royalties from sales related to these patents. ME is named on four of these five patent applications.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nordström, T., Eklund, M. & Grönberg, H. Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study—Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7. World J Urol 35, 895–896 (2017). https://doi.org/10.1007/s00345-016-1907-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-016-1907-2

Keywords

Search

Navigation